These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30085846)

  • 1. Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience.
    Asamoah FA; Yarney J; Awasthi S; Vanderpuye V; Venkat PS; Fink AK; Naghavi AO; Abrahams A; Mensah JE; Sasu E; Tagoe SNA; Johnstone PAS; Yamoah K
    J Glob Oncol; 2018 Jul; 4():1-13. PubMed ID: 30085846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
    Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact.
    Garibaldi E; Gabriele D; Maggio A; Delmastro E; Garibaldi M; Bresciani S; Ortega C; Stasi M; Gabriele P
    Panminerva Med; 2016 Jun; 58(2):121-9. PubMed ID: 26785374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma.
    Aizer AA; Yu JB; Colberg JW; McKeon AM; Decker RH; Peschel RE
    Radiother Oncol; 2009 Nov; 93(2):185-91. PubMed ID: 19800702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for
    Peters M; Smit Duijzentkunst DA; Westendorp H; van de Pol SMG; Kattevilder R; Schellekens A; van der Voort van Zyp JRN; Moerland MA; van Vulpen M; Hoekstra CJ
    Brachytherapy; 2017; 16(2):282-290. PubMed ID: 28110899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of race on biochemical disease recurrence after prostate brachytherapy.
    Yamoah K; Stone N; Stock R
    Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy.
    Chen WC; Tokita KM; Ravera J; Fu P; Jiang Y; Kaminsky DA; Ponsky L; Ellis RJ
    Brachytherapy; 2013; 12(5):422-7. PubMed ID: 23380382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
    Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
    Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer.
    Ganzer R; Fritsche HM; Brandtner A; Bründl J; Koch D; Wieland WF; Blana A
    BJU Int; 2013 Aug; 112(3):322-9. PubMed ID: 23356910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?
    Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
    Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Ludgate CM; Bishop DC; Pai H; Eldridge B; Lim J; Berthelet E; Blood P; Piercy GB; Steinhoff G
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1309-15. PubMed ID: 16029786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma.
    Ellis RJ; Vertocnik A; Sodee B; Zhou H; Kim E; Young B; Fu P; Colussi V; Spirnak JP; Dinchman KH; Resnick MI
    Brachytherapy; 2003; 2(4):215-22. PubMed ID: 15062129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active surveillance for localized prostate cancer: update of a prospective single-center cohort.
    Thostrup M; Thomsen FB; Iversen P; Brasso K
    Scand J Urol; 2018 Feb; 52(1):14-19. PubMed ID: 28958194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.